Pancreatic Cancer Research

ResearcherAffiliated Hospital of Guizhou Medical UniversityActive in the last 2 years

Peng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8462-2875; OpenAlex author ID A5100752011. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381-3p/MDM2 axis to activate the p53 signaling pathway. Last author DOI 10.1016/j.prp.2025.156186↗
  2. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03921-3↗
  3. Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals. Co-author DOI 10.1042/bsr20190610↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dongyun Cun · 1 shared paper, 2025 · strength 0.30
  2. Cuiping Wang · 1 shared paper, 2019 · strength 0.16
  3. Zhiwei He · 1 shared paper, 2021 · strength 0.14
  4. Xueyi Jiang · 1 shared paper, 2021 · strength 0.14
  5. Jian Xu · 1 shared paper, 2021 · strength 0.14
  6. Yankun Chen · 1 shared paper, 2021 · strength 0.14
  7. Xinyuan Liu · 1 shared paper, 2021 · strength 0.14
  8. Jianxin Jiang · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.